Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788564 | 1.00 | HTT (0.66) | HTTSMN1; SMN2ALDH1A1PDE4BHRH3 | |
| SCHEMBL519845 | 0.88 | HTT (0.70) | HTTSMN1; SMN2ALDH1A1PDE4BHRH3 | |
| SCHEMBL11296180 | 0.86 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1HRH3KMT2AMEN1 | |
| SCHEMBL16884088 | 0.86 | HTT (0.76) | HTTSMN1; SMN2ALDH1A1PDE4BKMT2A | |
| SCHEMBL4764968 | 0.86 | HTT (0.52) | HTTSMN1; SMN2ALDH1A1HRH3NCF1 | |
| SCHEMBL520387 | 0.86 | SIGMAR1 (0.55) | HTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL9995230 | 0.85 | GAA (0.60) | ALDH1A1HRH3KMT2AMEN1 | |
| SCHEMBL18970191 | 0.84 | ALDH1A1 (0.56) | HTTSMN1; SMN2ALDH1A1HRH3KMT2A | |
| SCHEMBL520829 | 0.84 | LMNA (0.57) | SMN1; SMN2ALDH1A1NCF1KMT2AMEN1 | |
| SCHEMBL29959053 | 0.84 | LMNA (0.57) | SMN1; SMN2ALDH1A1NCF1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-01 | — | — | US | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2019008011-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-10 | — | — | WO | disclosed |
| EP-2686318-B1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER REC TECH LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | HTT 3515/4885SMN1; SMN2 3490/4885ALDH1A1 3603/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | HTT 3769/4885SMN1; SMN2 3815/4885ALDH1A1 140/4885 |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, MAP3K14 | HTT 3450/4885SMN1; SMN2 3284/4885ALDH1A1 3864/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | HTT 786/4885SMN1; SMN2 4722/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.